Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

HIRU, PWRM, GERN, GME, BMJ Stock Market Report from DrStockPick.com

|Includes: Geron Corporation (GERN)

drstock-2-3

signup3m

 

http://bestotc.com/img/hiru_logo300x52.jpg

HIRU CORPORATION (Other OTC: HIRU.PK) subsidiary Shuangshi AHP Co.'s new production line and workshop are in their final stages. The new equipment is being put in place. The company announced on June 17, during the second annual Shuangshi AHP Co. board meeting, that the management decided to invest and expand on the company's vaccination production. Since then, the company invested $3 million RMB into the development of the two new production lines: a line for large volume injections and a line for injection powder.

Hiru Corporation, through its subsidiary, Jiangxi RongYu Pharmaceutical Group Co., Ltd., produces Chinese herbs for the naturopathic industry in China. It manufactures herbal supplements containing ginseng.

*********

power3

Power3 Medical Products, Inc. (OTC.BB:PWRM), a leading proteomics company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases, announced recently that it has signed a definitive agreement to acquire all of the stock of Rozetta-Cell Life Sciences, Inc. Power3 plans to effectuate the acquisition of Rozetta-Cell by merging Rozetta-Cell with and into Power3, with Power3 remaining as the surviving company in the merger. The acquisition of Rozetta-Cell is expected to be completed in October or November 2010.

Power3 Medical Products, Inc. is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig's disease).

*********

Geron Corporation (Nasdaq:GERN) reported the publication of preclinical data demonstrating that the company’s telomerase inhibitor drug, imetelstat (GRN163L), currently in Phase 2 clinical trials, targets cancer stem cells from multiple myeloma, pancreatic and breast cancers.

The first publication shows the inhibitory effect of imetelstat on multiple myeloma cancer stem cells in vitro and in animal models of the human disease. The research, published in the journal PLoS ONE, was co-authored by Dr. William Matsui and colleagues at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins and scientists from GERN.

The second publication demonstrates the inhibitory effect of imetelstat on cancer stem cells from breast and pancreatic tumor cell lines in vitro and in animal models of the human disease. The data, published in the journal Cancer Research, were co-authored by Geron scientists and Professors Jerry Shay and Woodring Wright at the University of Texas Southwestern Medical Center at Dallas.

*********

GameStop Corp. (NYSE:GME) reported the addition of Sony downloadable content (NYSE:DLC) to its current digital catalog of add-on content.

Earlier this year, GME pioneered the technology of selling digital downloadable content in more than 4,400 U.S. stores, making it the only brick and mortar retailer of such content.

*********

Birks & Mayors Inc. (AMEX:BMJ), which operates 67 luxury jewelry stores across Canada, Florida and Georgia, reported that the Company will conduct a conference call on Thursday, November 18, 2010 at 4:45 pm Eastern Time, to discuss results for the first half of Fiscal 2011.

 

 

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (OTCPK:CRWE) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (OTCPK:CRWE), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (OTCPK:CRWE) advertises for a particular client, Crown Equity Holdings Inc. (OTCPK:CRWE) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (OTCPK:CRWE), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (OTCPK:CRWE) has received five thousand dollars and anticipates receiving another forty five thousand dollars in cash from a third party for (thirty) days of advertising for Hiru Corporation (OTCPK:HIRU) Crown Equity Holdings Inc. (OTCPK:CRWE) has received 1,000,000 shares 144 restricted stocks for IT department services from Power 3 Medical Products Inc. (OTC:PWRM).

drstbc